Skip to content

Sagimet Biosciences Inc.

SGMT

CIK 0001400118

← back to feed
Revenue (TTM)
$2M
Q1 Mar 2026
Net Income (TTM)
−$52.12M
−12.0% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$1.61
−9.0% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-2,891.9%
Q1 Mar 2026
Net Margin
-2,606.0%
Q1 Mar 2026
Free Cash Flow (TTM)
—
Q1 Mar 2026
Cash
$36.63M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
30.67M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings